Mark Payne

With Republicans set to take control of Congress and the White House, lame-duck lawmakers on Capitol Hill are in a mad dash to pass legislation ahead of the new year. Many are turning an eye toward making permanent the telehealth extensions that became available during the pandemic.

With Republicans set to take control of Congress and the White House, lame-duck lawmakers on Capitol Hill are in a mad dash to pass legislation ahead of the new year. Many are turning an eye toward making permanent the telehealth extensions that became available during the pandemic.

The U.S. Supreme Court on Tuesday grappled with whether a change to a formula used to calculate billions of dollars in payments every year to hospitals treating a large share of low-income patients would lead to shutdowns of rural and "safety net" hospitals.

With Americans focused on a presidential election unlike any in U.S. history, all's forgiven if you're not up on the latest healthcare case at the U.S. Supreme Court.

The Senate Judiciary Committee on Tuesday railed against drugmakers and pharmacy benefit managers for allegedly causing the high cost of prescription drugs, arguing that "Big Pharma" has used anticompetitive tactics through patenting to fleece American patients.

Feds Ask Justices For 'GVR' In Abortion Guidance Case

A D.C. federal judge on Friday agreed to toss a lawsuit brought by a group of hospitals against the U.S. Department of Health and Human Services challenging its Medicare payment determinations for low-income patients, finding the hospitals didn't exhaust their administrative remedies. 

When Texan Kyleigh Thurman showed up at a hospital in central Texas with an ectopic pregnancy, she alleges that physicians' confusion over the state's strict abortion ban led to inaction and delays in her federally protected care.

Six of the nation's leading hospital associations told the Supreme Court on Wednesday that the U.S. Department of Health and Human Services is being "stingy" when miscalculating a formula that could cost hospitals treating low-income patients more than a billion dollars in special payments each year. 

This spring, despite widespread industry opposition, the U.S. Food and Drug Administration granted itself oversight of laboratory-developed diagnostic tests. Now, industry groups say they're facing a costly and convoluted agency approval process — one they hope they can dismantle based on the Supreme Court's recent decision to overturn Chevron deference.